Does the Addition of Cetuximab to Radiochemotherapy Improve Outcome of Patients with Locally Advanced Rectal Cancer? Long-Term Results from Phase II Trials

Table 2

Pathohistological results of patients with locally advanced rectal cancer receiving capecitabine/irinotecan +/− cetuximab based chemoradiotherapy as preoperative treatment.

	Capecitabine/irinotecan ()	Capecitabine/irinotecan + cetuximab ()	value
ypT downstaging, (%)
ypT0	7 (19)	4 (8)
ypT1	5 (14)	1 (2)
ypT2	11 (30)	18 (37)
ypT3	12 (32)	24 (49)
ypT4	2 (5)	2 (4)
Chi square			0.11
ypN−	23 (62)	36 (73)
ypN+	14 (38)	13 (27)
Fisher’s exact test			0.35
R0 resection, (%)
	36 (97)	48 (98)
Fisher’s exact test			1.00
Pathologic complete remission ypT0 pN0, (%)
	7 (19)	4 (8)
Fisher’s exact test			0.19
T-downstaging (ypT0-2, pN0), (%)
	9 (24)	21 (43)
Fisher’s exact test			0.11